Fagron (EBR: FAGR) Fagron is a leading global company active in pharmaceutical compounding focused on delivering personalized medicine to hospitals, pharmacies, clinics and patients in 36 countries around the world. The company is pursuing an active buy-and-build strategy and combines high organic growth with acquisitions across its three major markets: Europe, North America and South America.
Alychlo has a long history with Fagron and has been a shareholder since its IPO in 2007. Alychlo acted as a cornerstone investor in the company's € 220 million capital increase in 2016 and is currently Fagron's reference shareholder with a stake of approx. 10%.
For more information: www.fagron.com